Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Clinical trial NCT06343064 · RECRUITING
Trial details
- NCT number
- NCT06343064
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-13
- Primary completion
- 2026-12-31
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.